Subscribe

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Enhertu Received Regular FDA Approval for Patients with Unresectable or Metastatic Breast Cancer

JHOP - June 2022 Vol 12, No 3 - FDA Oncology Update, Breast Cancer
Download PDF

On May 4, 2022, the FDA granted a regular full approval for fam-trastuzumab deruxtecan-nxki (Enhertu; Daiichi Sankyo) for adults with unresectable or metastatic HER2-positive breast cancer who had previously received an anti-HER2 regimen in the metastatic or the neoadjuvant or adjuvant setting whose disease recurred during or within 6 months of completing therapy, based on the confirmatory DESTINY-Breast03 clinical trial.

“Enhertu has demonstrated significant progression-free survival in the earlier metastatic setting, potentially establishing it as a new standard of care in previously treated patients with HER2-positive metastatic breast cancer. Today’s approval is an important milestone for the clinical community as we will now be able to offer Enhertu to these patients earlier in their treatment,” said Erika Hamilton, MD, Director of the Breast Cancer and Gynecological Cancer Research Program, Sarah Cannon Research Institute, Nashville, TN, in a press release.

This regular approval was based on the results of the confirmatory clinical trial DESTINY-Breast03 conducted after the December 2019 FDA accelerated approval for fam-trastuzumab deruxtecan for adults with unresectable or metastatic HER2-positive breast cancer who have received ≥2 anti-HER2 regimens in the metastatic setting.

The DESTINY-Breast03 study was a multicenter, open-label, randomized clinical trial of 524 patients with HER2-positive, unresectable, and/or metastatic breast cancer who had received trastuzumab and taxane therapy for metastatic disease or whose disease recurred during or within 6 months of completing neoadjuvant or adjuvant therapy. Patients were randomized (1:1) to intravenous fam-trastuzumab deruxtecan or to ado-trastuzumab emtansine every 3 weeks, until disease progression or unacceptable adverse events.

The main efficacy outcome measure was progression-free survival (PFS). Key secondary end points were overall survival (OS) and confirmed objective response rate (ORR). The median PFS was not reached (95% confidence interval [CI], 18.5-not estimable) in the fam-trastuzumab deruxtecan arm and was 6.8 months (95% CI, 5.6-8.2) in the ado-trastuzumab emtansine arm. The hazard ratio was 0.28 (95% CI, 0.22-0.37; P <.0001). At the time of the PFS analysis, 16% of patients had died and the OS was immature. The ORR was 82.7% (95% CI, 77.4-87.2) and 36.1% (95% CI, 30.0-42.5), respectively.

The most common (incidence >30%) adverse reactions with fam-trastuzumab deruxtecan were nausea, fatigue, vomiting, alopecia, constipation, anemia, and musculoskeletal pain. Serious adverse reactions in >1% of patients with this drug were vomiting, interstitial lung disease, pneumonia, pyrexia, and urinary tract infection. The prescribing information of fam-trastuzumab deruxtecan includes a warning about the risk for interstitial lung disease and embryo-fetal toxicity.

Related Items
Epkinly FDA Approved for Relapsed or Refractory Diffuse Large B-Cell Lymphoma or High-Grade B-Cell Lymphoma
Online First published on June 5, 2023 in FDA Oncology Update
Lynparza FDA Approved, in Combination With Abiraterone and Prednisone (or Prednisolone), for Metastatic Castration-Resistant Prostate Cancer With BRCA Mutation
Online First published on June 5, 2023 in FDA Oncology Update
Polivy Received New Indication for First-Line Treatment of Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, and High-Grade B-Cell Lymphoma
Online First published on June 5, 2023 in FDA Oncology Update
Omisirge FDA Approved for Patients with Hematologic Malignancies to Reduce Time to Neutrophil Recovery and Infection
Online First published on May 12, 2023 in FDA Oncology Update
Padcev plus Keytruda Granted Accelerated FDA Approval for Locally Advanced or Metastatic Urothelial Carcinoma
Online First published on April 24, 2023 in FDA Oncology Update
FDA Approved Zynyz for Metastatic or Recurrent Locally Advanced Merkel-Cell Carcinoma
JHOP - April 2023 Vol 13, No 2 published on March 31, 2023 in FDA Oncology Update
FDA Approved Tafinlar plus Mekinist for Pediatric Patients with BRAF V600E Mutation–Positive Low-Grade Glioma
JHOP - April 2023 Vol 13, No 2 published on March 31, 2023 in FDA Oncology Update
FDA Granted Jemperli Regular Approval for dMMR Endometrial Cancer
JHOP - April 2023 Vol 13, No 2 published on March 31, 2023 in FDA Oncology Update
FDA Expanded Eligibility for Verzenio plus Endocrine Therapy in Patients with Early Breast Cancer
JHOP - April 2023 Vol 13, No 2 published on March 31, 2023 in FDA Oncology Update
Trodelvy Now FDA Approved for HR-Positive, HER2-Negative Breast Cancer
JHOP - April 2023 Vol 13, No 2 published on March 31, 2023 in FDA Oncology Update
© Amplity Health. All rights reserved.